A Look At The Legality Behind Daraprim's Price Spike

Law360, New York (September 30, 2015, 12:15 PM EDT) -- Turing Pharmaceuticals AG and its controversial CEO Martin Shkreli recently made headlines when Turing raised the price of its antiprotozal drug Daraprim (pyrimethamine) from $13.50 to $750 per tablet.[1] The price increase received significant media attention.

Here, we evaluate Turing's Daraprim price hike from a legal perspective, including an analysis of the mechanisms used to balance innovation and drug pricing in the U.S., and their degree of application, if any, to the drug's recent price hike.

Balancing Drug Prices and Innovation

The United States has traditionally incentivized drug development innovation. Patents and the U.S. Food and Drug Administration's regulatory exclusivities allow...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!